Patent classifications
C07D515/22
Macrocyclic indoles as Mcl-1 inhibitors
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, R.sup.1h, L.sup.2, L.sup.3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer. ##STR00001##
Macrocyclic indoles as Mcl-1 inhibitors
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, R.sup.1h, L.sup.2, L.sup.3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer. ##STR00001##
MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, L.sup.1, L.sup.2, L.sup.3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
##STR00001##
MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, L.sup.1, L.sup.2, L.sup.3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
##STR00001##
MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3 inhibition.
##STR00001##
MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3 inhibition.
##STR00001##
MACROCYCLIC INDOLES AS MCL-1 INHIBITORS
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, R.sup.1h, L.sup.2, L.sup.3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
##STR00001##
MACROCYCLIC INDOLES AS MCL-1 INHIBITORS
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R.sup.1a, R.sup.1b, R.sup.1h, L.sup.2, L.sup.3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
##STR00001##
MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.